A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients

Trial Profile

A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2018

At a glance

  • Drugs Treprostinil (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Registrational
  • Acronyms INSPIRE
  • Sponsors Liquidia Technologies
  • Most Recent Events

    • 10 Jan 2018 New trial record
    • 03 Jan 2018 According to the Liquidia Technologies media release, based on the feedback from the FDA, data from this trial will support a potential U.S. regulatory approval of LIQ861.
    • 03 Jan 2018 According to the Liquidia Technologies media release, company will enroll first patient in the next few weeks and topline data are expected in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top